Mashaal Michael Y 4
4 · ReShape Lifesciences Inc. · Filed Dec 21, 2017
Insider Transaction Report
Form 4
Mashaal Michael Y
Director
Transactions
- Conversion
Common Stock, $0.01 par value per share
2017-12-19+2,048,700→ 2,617,077 total(indirect: See footnote) - Sale
Series C Convertible Preferred Stock, $0.01 par value
2017-12-19−20,487→ 26,200 total(indirect: See footnote)
Footnotes (2)
- [F1]Each share of Series C Convertible Preferred Stock converted into 100 shares of common stock.
- [F2]Consists of shares held directly by HealthCor Partners Fund II, L.P. ("HCPII"). The shares held by HCPII may be deemed to be beneficially owned by HealthCor Partners II, L.P. ("HCP2LP"), its general partner, and by HealthCor Partners GP, LLC ("HCPGP"), the general partner of HCP2LP. Dr. Mashaal is a managing director of HealthCor Partners Management, L.P. ("HCP Management"), which is the investment manager to HCPII, and may be deemed to have shared voting and investment power over such shares. Each of HCPLP, HCP2LP, HCPGP, HCP Management and Dr. Mashaal hereby disclaims any beneficial ownership of shares held by HCPII except to the extent of any pecuniary interest therein.